Sorilux Approval History
- FDA approved: Yes (First approved October 7th, 2010)
- Brand name: Sorilux
- Generic name: calcipotriene
- Dosage form: Foam
- Company: Stiefel Laboratories, Inc.
- Treatment for: Psoriasis
Sorilux (calcipotriene) Foam is a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients aged 18 years and older.
Development History and FDA Approval Process for Sorilux
|Oct 12, 2010||Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005%|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.